Orphazyme A/S ADR (ORPH) News
Filter ORPH News Items
ORPH News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ORPH News Highlights
- For ORPH, its 30 day story count is now at 9.
- Over the past 23 days, the trend for ORPH's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about ORPH are DK, KIM and CNTG.
Latest ORPH News From Around the Web
Below are the latest news stories about Orphazyme A that investors may wish to consider to help them evaluate ORPH as an investment opportunity.
Orphazyme announces update on regulatory review of arimoclomol in the European UnionOrphazyme A/SCompany announcementNo. 07/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 23, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a late-stage biopharmaceutical company, today announced an update on the ongoing review of the Marketing Authorisation Application (MAA) for its investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C (NPC) by the Committee for Medicinal Products |
Capital increase of 360,000 shares in Orphazyme A/S as a result of the utilization of the U.S. At-the-Market Offering ProgramOrphazyme A/SCompany announcementNo. 06/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 18, 2022 – Orphazyme A/S (ORPHA.CO (DK); ORPH (US)) (the “Company”), a late-stage biopharmaceutical company, announces that the Company has issued new shares in the period from Friday, February 11, 2022 to Thursday, February 17, 2022 as a result of the utilization of the Company’s U.S. At-the-Market Offering Program with Cowen and Company, LLC (“Cowen”). On February 11, 20 |
Resolutions passed at the Extraordinary General MeetingOrphazyme A/SCompany announcementNo. 05/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 15, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today held an Extraordinary General Meeting, at which the general meeting: Approved the authorizations to the Board of Directors and amendments to the articles of |
Amendment of proposals put forward at the Extraordinary General MeetingOrphazyme A/SCompany announcementNo. 04/2022 www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 14, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the Board of Directors has decided to limit the scope of the proposed authorizations set forward under items 1.2, 1.3 and 1.4 of the agenda o |
Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare DrugOrphazyme (ORPH) is looking to resubmit its NDA for arimoclomol to the FDA for the treatment of Niemann-Pick disease type C in the United States. Shares rise. |
Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type C in the United StatesOrphazyme A/SInvestor newsNo. 02/2022www.orphazyme.comCompany Registration No. 32266355 Orphazyme has made progress towards resubmission of the NDA for arimoclomol to the FDA and plans to request a Type C Meeting in Q2 2022Subject to these discussions, the Company aims to resubmit the NDA during H2 2022 Copenhagen, Denmark, February 11, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the t |
Orphazyme to present additional data on arimoclomol’s mechanism of action during 2022 Annual WORLDSymposium™Orphazyme A/SInvestor NewsNo. 01/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, February 7, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced it will present new non-clinical data on its investigational drug arimoclomol during the 18th Annual WORLDSymposium™ Scientific Meeting, to be held in San |
CENTOGENE Announces Nomination of Kim Stratton as Chief Executive OfficerDr. Andrin Oswald resigns as CEO due to prolonged medical leave; Kim Stratton elected as successorCAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the Company’s Supervisory Board’s nomination of Kim Stratton as Chief Executive Officer, transitioning from her prior designation as Interim CEO. In h |
Changes to the Executive Management of Orphazyme – Anders Vadsholt to be appointed CEOOrphazyme A/SCompany announcementNo. 03/2022Inside informationwww.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, January 31, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that Chief Executive Officer (CEO) Christophe Bourdon will resign from his position as CEO at Orphazyme A/S to take on the role as |
Notice to convene Extraordinary General MeetingOrphazyme A/SCompany announcement No. 02/2022www.orphazyme.comCompany Registration No. 32266355 Copenhagen, Denmark, January 24, 2022 – Orphazyme A/S (ORPHA.CO; ORPH) (the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that an Extraordinary General Meeting of the Company will be held on: Tuesday, February 15, 2022 at 5:00 PM (CET) at the Company’s address Ole Maaløes Vej 3, DK-2 |